Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 101 | 2023 | 878 | 11.050 |
Why?
|
Transplantation Conditioning | 41 | 2020 | 373 | 4.480 |
Why?
|
Graft vs Host Disease | 44 | 2023 | 365 | 3.640 |
Why?
|
Transplantation, Homologous | 76 | 2020 | 996 | 3.350 |
Why?
|
Hematologic Neoplasms | 24 | 2023 | 329 | 3.020 |
Why?
|
Multiple Myeloma | 13 | 2020 | 307 | 1.830 |
Why?
|
Lymphoma | 11 | 2017 | 262 | 1.790 |
Why?
|
Graft vs Tumor Effect | 13 | 2015 | 25 | 1.770 |
Why?
|
Lymphoma, Non-Hodgkin | 12 | 2012 | 261 | 1.450 |
Why?
|
Leukemia, Myeloid, Acute | 16 | 2017 | 763 | 1.380 |
Why?
|
Lymphocyte Transfusion | 7 | 2013 | 41 | 1.300 |
Why?
|
Transplantation, Autologous | 20 | 2020 | 331 | 1.280 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 11 | 2017 | 136 | 1.270 |
Why?
|
T-Lymphocytes | 17 | 2021 | 1195 | 1.260 |
Why?
|
Bone Marrow Transplantation | 17 | 2019 | 286 | 1.220 |
Why?
|
Stem Cell Transplantation | 10 | 2020 | 183 | 1.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2019 | 2438 | 1.150 |
Why?
|
Salvage Therapy | 4 | 2012 | 233 | 1.020 |
Why?
|
Myelodysplastic Syndromes | 13 | 2017 | 346 | 1.000 |
Why?
|
Immunotherapy, Adoptive | 9 | 2021 | 170 | 0.990 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 5 | 2019 | 151 | 0.960 |
Why?
|
Transplantation Chimera | 7 | 2015 | 80 | 0.950 |
Why?
|
Lymphocyte Depletion | 7 | 2017 | 97 | 0.930 |
Why?
|
Hodgkin Disease | 8 | 2017 | 177 | 0.840 |
Why?
|
Humans | 138 | 2023 | 86644 | 0.820 |
Why?
|
Adult | 81 | 2023 | 25648 | 0.810 |
Why?
|
Graft Survival | 10 | 2016 | 884 | 0.800 |
Why?
|
Blood Component Removal | 2 | 2020 | 24 | 0.800 |
Why?
|
Jehovah's Witnesses | 1 | 2021 | 18 | 0.780 |
Why?
|
Middle Aged | 75 | 2020 | 25028 | 0.770 |
Why?
|
Leukemia | 10 | 2011 | 320 | 0.770 |
Why?
|
Granulocyte Colony-Stimulating Factor | 10 | 2008 | 165 | 0.740 |
Why?
|
Myeloablative Agonists | 4 | 2019 | 34 | 0.730 |
Why?
|
Monitoring, Physiologic | 2 | 2012 | 268 | 0.720 |
Why?
|
Female | 84 | 2021 | 44533 | 0.690 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 6 | 2015 | 67 | 0.680 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2013 | 425 | 0.660 |
Why?
|
Male | 74 | 2019 | 40966 | 0.650 |
Why?
|
Tissue Donors | 9 | 2020 | 463 | 0.630 |
Why?
|
Breast Neoplasms | 9 | 2011 | 2903 | 0.600 |
Why?
|
Treatment Outcome | 35 | 2019 | 7993 | 0.590 |
Why?
|
Aged | 41 | 2020 | 18415 | 0.580 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2019 | 93 | 0.570 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 3 | 0.560 |
Why?
|
Lymphoma, T-Cell | 1 | 2016 | 48 | 0.540 |
Why?
|
Hematopoietic Stem Cells | 6 | 2019 | 292 | 0.510 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2020 | 1313 | 0.510 |
Why?
|
Cytokines | 6 | 2021 | 776 | 0.510 |
Why?
|
Antigens, Neoplasm | 3 | 2012 | 325 | 0.500 |
Why?
|
Th2 Cells | 4 | 2013 | 146 | 0.490 |
Why?
|
Recurrence | 15 | 2017 | 1139 | 0.490 |
Why?
|
Disease-Free Survival | 17 | 2019 | 1204 | 0.490 |
Why?
|
Cyclophosphamide | 10 | 2023 | 299 | 0.480 |
Why?
|
Adoptive Transfer | 2 | 2004 | 168 | 0.460 |
Why?
|
Geriatric Assessment | 4 | 2020 | 166 | 0.440 |
Why?
|
Interleukin-7 | 2 | 2012 | 41 | 0.440 |
Why?
|
Immunization | 1 | 2012 | 158 | 0.420 |
Why?
|
Education | 2 | 2011 | 58 | 0.410 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2010 | 375 | 0.380 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2012 | 123 | 0.380 |
Why?
|
Etoposide | 8 | 2019 | 196 | 0.380 |
Why?
|
Neoplasms | 5 | 2018 | 2898 | 0.380 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 4 | 2000 | 16 | 0.370 |
Why?
|
Antineoplastic Agents | 11 | 2017 | 2360 | 0.370 |
Why?
|
Thionucleotides | 4 | 2000 | 56 | 0.370 |
Why?
|
Vincristine | 5 | 2019 | 111 | 0.360 |
Why?
|
Hematopoiesis | 5 | 2019 | 163 | 0.350 |
Why?
|
HLA Antigens | 6 | 2016 | 232 | 0.350 |
Why?
|
Survival Rate | 15 | 2014 | 1863 | 0.350 |
Why?
|
Adolescent | 25 | 2016 | 8981 | 0.350 |
Why?
|
Congresses as Topic | 1 | 2010 | 116 | 0.350 |
Why?
|
Doxorubicin | 5 | 2019 | 295 | 0.330 |
Why?
|
Remission Induction | 11 | 2017 | 722 | 0.330 |
Why?
|
National Cancer Institute (U.S.) | 7 | 2013 | 70 | 0.330 |
Why?
|
Survival Analysis | 15 | 2017 | 1538 | 0.320 |
Why?
|
Neoplasm, Residual | 5 | 2013 | 162 | 0.320 |
Why?
|
Oligonucleotides, Antisense | 3 | 1997 | 69 | 0.320 |
Why?
|
Prednisone | 4 | 2019 | 258 | 0.320 |
Why?
|
Vidarabine | 5 | 2019 | 141 | 0.310 |
Why?
|
Graft Rejection | 5 | 2016 | 1065 | 0.290 |
Why?
|
Rituximab | 3 | 2019 | 116 | 0.290 |
Why?
|
Graft vs Leukemia Effect | 3 | 2013 | 11 | 0.290 |
Why?
|
Secondary Prevention | 7 | 2013 | 162 | 0.290 |
Why?
|
Lymphoma, B-Cell | 2 | 2020 | 103 | 0.280 |
Why?
|
Severity of Illness Index | 3 | 2010 | 1801 | 0.280 |
Why?
|
Interleukin-4 | 1 | 2006 | 127 | 0.280 |
Why?
|
Immunosuppressive Agents | 6 | 2019 | 977 | 0.280 |
Why?
|
Young Adult | 14 | 2021 | 5976 | 0.260 |
Why?
|
Combined Modality Therapy | 13 | 2012 | 1686 | 0.250 |
Why?
|
Prospective Studies | 10 | 2020 | 4214 | 0.250 |
Why?
|
Registries | 2 | 2007 | 702 | 0.250 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2010 | 173 | 0.240 |
Why?
|
Sirolimus | 3 | 2015 | 169 | 0.230 |
Why?
|
Child, Preschool | 8 | 2016 | 3612 | 0.220 |
Why?
|
Cell- and Tissue-Based Therapy | 2 | 2021 | 49 | 0.220 |
Why?
|
Histocompatibility Testing | 5 | 2017 | 154 | 0.220 |
Why?
|
Transplantation Immunology | 4 | 2013 | 84 | 0.220 |
Why?
|
Retrospective Studies | 18 | 2019 | 8489 | 0.220 |
Why?
|
Whole-Body Irradiation | 5 | 2019 | 63 | 0.210 |
Why?
|
Fetal Blood | 3 | 2017 | 90 | 0.210 |
Why?
|
Time Factors | 8 | 2013 | 5210 | 0.210 |
Why?
|
Bone Marrow Purging | 3 | 2002 | 7 | 0.210 |
Why?
|
Flow Cytometry | 4 | 2012 | 679 | 0.200 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 18 | 0.200 |
Why?
|
Child | 11 | 2016 | 6927 | 0.190 |
Why?
|
Immunophenotyping | 4 | 2016 | 211 | 0.190 |
Why?
|
Leukocyte Transfusion | 1 | 2000 | 15 | 0.190 |
Why?
|
Antibodies, Monoclonal | 3 | 2017 | 1376 | 0.190 |
Why?
|
Haplotypes | 3 | 2019 | 642 | 0.180 |
Why?
|
United States | 11 | 2020 | 6672 | 0.180 |
Why?
|
Clinical Trials as Topic | 6 | 2011 | 1169 | 0.180 |
Why?
|
Glucocorticoids | 2 | 2015 | 352 | 0.180 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 44 | 0.180 |
Why?
|
Interleukin-15 | 2 | 2012 | 72 | 0.180 |
Why?
|
Unrelated Donors | 2 | 2017 | 50 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 860 | 0.170 |
Why?
|
Janus Kinase 2 | 1 | 2019 | 57 | 0.170 |
Why?
|
Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
Quality of Life | 3 | 2013 | 1585 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 120 | 0.160 |
Why?
|
Killer Cells, Natural | 5 | 2011 | 267 | 0.160 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 1673 | 0.160 |
Why?
|
Transcriptional Activation | 1 | 2019 | 280 | 0.160 |
Why?
|
CD3 Complex | 2 | 2008 | 135 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 189 | 0.160 |
Why?
|
Chronic Disease | 8 | 2012 | 971 | 0.160 |
Why?
|
Multicenter Studies as Topic | 2 | 2011 | 159 | 0.150 |
Why?
|
Antigens, CD34 | 4 | 2017 | 158 | 0.150 |
Why?
|
Disease Management | 1 | 2019 | 327 | 0.150 |
Why?
|
Preoperative Care | 1 | 2019 | 397 | 0.150 |
Why?
|
Power Plants | 1 | 1997 | 5 | 0.150 |
Why?
|
Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
Radioactive Hazard Release | 1 | 1997 | 8 | 0.150 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 295 | 0.150 |
Why?
|
CD4 Lymphocyte Count | 2 | 2008 | 66 | 0.150 |
Why?
|
Prognosis | 8 | 2018 | 3679 | 0.140 |
Why?
|
Survivors | 3 | 2013 | 226 | 0.140 |
Why?
|
Neoplasms, Second Primary | 1 | 1999 | 252 | 0.140 |
Why?
|
Acute Disease | 4 | 2013 | 826 | 0.140 |
Why?
|
Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
Haploidy | 1 | 2016 | 31 | 0.140 |
Why?
|
Neoplasm Metastasis | 4 | 2015 | 1056 | 0.140 |
Why?
|
Anthracyclines | 1 | 2016 | 37 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2020 | 372 | 0.140 |
Why?
|
Lymphoproliferative Disorders | 3 | 2011 | 107 | 0.140 |
Why?
|
Lymphocytes | 1 | 1998 | 464 | 0.140 |
Why?
|
Blood Donors | 1 | 2015 | 26 | 0.140 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2017 | 159 | 0.130 |
Why?
|
Radiation Injuries | 1 | 1997 | 155 | 0.130 |
Why?
|
Community-Acquired Infections | 1 | 2015 | 63 | 0.130 |
Why?
|
Proto-Oncogene Proteins | 1 | 2019 | 645 | 0.130 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 78 | 0.130 |
Why?
|
Preoperative Period | 2 | 2018 | 91 | 0.130 |
Why?
|
Respiratory Tract Infections | 1 | 2015 | 105 | 0.130 |
Why?
|
Donor Selection | 1 | 2015 | 67 | 0.130 |
Why?
|
Medical Oncology | 2 | 2009 | 359 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Pilot Projects | 4 | 2020 | 839 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
Cause of Death | 3 | 2018 | 277 | 0.120 |
Why?
|
Comorbidity | 3 | 2018 | 943 | 0.120 |
Why?
|
Risk Factors | 8 | 2018 | 5417 | 0.120 |
Why?
|
Consensus | 1 | 2015 | 335 | 0.120 |
Why?
|
Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 266 | 0.120 |
Why?
|
Antigens, CD19 | 1 | 2013 | 39 | 0.120 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2006 | 315 | 0.120 |
Why?
|
Immunomodulation | 1 | 2013 | 55 | 0.120 |
Why?
|
Disease Progression | 5 | 2016 | 1531 | 0.120 |
Why?
|
Transplantation, Haploidentical | 3 | 2017 | 27 | 0.110 |
Why?
|
Cohort Studies | 8 | 2014 | 2767 | 0.110 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2000 | 112 | 0.110 |
Why?
|
Neutrophils | 3 | 2019 | 307 | 0.110 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 1208 | 0.110 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2007 | 559 | 0.110 |
Why?
|
Hemocyanins | 1 | 2012 | 7 | 0.110 |
Why?
|
Immunoglobulin Idiotypes | 1 | 2012 | 12 | 0.110 |
Why?
|
Health Status | 2 | 2013 | 360 | 0.110 |
Why?
|
Immunity, Innate | 1 | 2016 | 409 | 0.110 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2012 | 6 | 0.110 |
Why?
|
Drug Resistance | 1 | 2013 | 256 | 0.110 |
Why?
|
Th1 Cells | 1 | 2013 | 164 | 0.100 |
Why?
|
Recombinant Proteins | 4 | 2008 | 1014 | 0.100 |
Why?
|
Chimerism | 3 | 2020 | 37 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2008 | 1991 | 0.100 |
Why?
|
Epitopes | 1 | 2012 | 255 | 0.100 |
Why?
|
Immunity, Cellular | 1 | 2012 | 177 | 0.100 |
Why?
|
Infant | 4 | 2013 | 3047 | 0.100 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2012 | 107 | 0.100 |
Why?
|
Recovery of Function | 2 | 2019 | 272 | 0.100 |
Why?
|
Sickness Impact Profile | 2 | 2011 | 27 | 0.100 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2012 | 273 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2011 | 50 | 0.100 |
Why?
|
Stress, Psychological | 1 | 2013 | 313 | 0.090 |
Why?
|
Peritoneal Neoplasms | 1 | 2012 | 177 | 0.090 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 689 | 0.090 |
Why?
|
Herpesvirus 4, Human | 1 | 2011 | 114 | 0.090 |
Why?
|
Filgrastim | 2 | 2000 | 56 | 0.090 |
Why?
|
Adaptation, Psychological | 1 | 2011 | 157 | 0.090 |
Why?
|
Group Processes | 1 | 2010 | 31 | 0.090 |
Why?
|
Risk Assessment | 2 | 2008 | 2261 | 0.090 |
Why?
|
B-Lymphocytes | 3 | 2011 | 724 | 0.090 |
Why?
|
Sarcoma | 1 | 2011 | 215 | 0.090 |
Why?
|
Prednisolone | 2 | 2012 | 41 | 0.090 |
Why?
|
Peptide Library | 1 | 2009 | 84 | 0.090 |
Why?
|
Tumor Lysis Syndrome | 2 | 2013 | 9 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2006 | 1939 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 916 | 0.090 |
Why?
|
Thiazoles | 1 | 2010 | 131 | 0.090 |
Why?
|
Neuroblastoma | 1 | 2013 | 374 | 0.090 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 1036 | 0.090 |
Why?
|
Up-Regulation | 2 | 2008 | 712 | 0.080 |
Why?
|
Postoperative Period | 1 | 2010 | 303 | 0.080 |
Why?
|
Animals | 7 | 2009 | 26582 | 0.080 |
Why?
|
CD8 Antigens | 1 | 2008 | 82 | 0.080 |
Why?
|
Aged, 80 and over | 5 | 2019 | 6509 | 0.080 |
Why?
|
Proportional Hazards Models | 2 | 2009 | 859 | 0.080 |
Why?
|
Myeloproliferative Disorders | 1 | 2010 | 110 | 0.080 |
Why?
|
Living Donors | 2 | 2008 | 339 | 0.080 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2008 | 50 | 0.080 |
Why?
|
Siblings | 1 | 2008 | 111 | 0.080 |
Why?
|
Immunocompromised Host | 1 | 2009 | 140 | 0.080 |
Why?
|
Biomarkers | 2 | 2019 | 1718 | 0.080 |
Why?
|
Leukocyte Count | 2 | 2016 | 220 | 0.080 |
Why?
|
Lymphocytosis | 1 | 2007 | 10 | 0.080 |
Why?
|
Vulvovaginitis | 1 | 2007 | 3 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2013 | 3640 | 0.080 |
Why?
|
Bioethical Issues | 1 | 2007 | 38 | 0.080 |
Why?
|
Lymphocyte Count | 1 | 2007 | 94 | 0.080 |
Why?
|
Receptors, Immunologic | 1 | 2008 | 135 | 0.080 |
Why?
|
Salivary Proteins and Peptides | 1 | 2007 | 5 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2001 | 381 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 1384 | 0.070 |
Why?
|
Pyrimidines | 1 | 2010 | 370 | 0.070 |
Why?
|
Estrogens | 1 | 2007 | 200 | 0.070 |
Why?
|
Stem Cells | 1 | 2009 | 351 | 0.070 |
Why?
|
Histocompatibility | 3 | 2016 | 71 | 0.070 |
Why?
|
PUVA Therapy | 1 | 2006 | 24 | 0.070 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2020 | 930 | 0.070 |
Why?
|
Saliva | 1 | 2007 | 122 | 0.070 |
Why?
|
Proteome | 1 | 2007 | 124 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2010 | 589 | 0.070 |
Why?
|
Emergency Service, Hospital | 1 | 2009 | 484 | 0.060 |
Why?
|
Melphalan | 2 | 2019 | 98 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2006 | 152 | 0.060 |
Why?
|
Conjunctivitis | 1 | 2004 | 6 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2006 | 552 | 0.060 |
Why?
|
Interleukin-1 | 1 | 2004 | 71 | 0.060 |
Why?
|
Risk | 2 | 2011 | 674 | 0.060 |
Why?
|
Cicatrix | 1 | 2004 | 63 | 0.060 |
Why?
|
Incidence | 5 | 2015 | 1577 | 0.060 |
Why?
|
Cancer Vaccines | 1 | 2005 | 156 | 0.060 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2004 | 35 | 0.060 |
Why?
|
Inflammation | 1 | 2009 | 920 | 0.060 |
Why?
|
Allografts | 2 | 2015 | 172 | 0.060 |
Why?
|
Vaccination | 1 | 2005 | 254 | 0.060 |
Why?
|
Urate Oxidase | 1 | 2003 | 11 | 0.060 |
Why?
|
Placebos | 2 | 2000 | 218 | 0.060 |
Why?
|
Models, Animal | 1 | 2004 | 263 | 0.060 |
Why?
|
Australia | 1 | 2023 | 99 | 0.060 |
Why?
|
Trastuzumab | 1 | 2003 | 68 | 0.060 |
Why?
|
Hyperuricemia | 1 | 2003 | 27 | 0.060 |
Why?
|
Monocytes | 1 | 2004 | 214 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2004 | 263 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2003 | 1823 | 0.050 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2003 | 213 | 0.050 |
Why?
|
Idarubicin | 1 | 2001 | 8 | 0.050 |
Why?
|
Models, Biological | 1 | 2009 | 1749 | 0.050 |
Why?
|
Cell Survival | 2 | 2001 | 969 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2002 | 293 | 0.050 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2001 | 126 | 0.050 |
Why?
|
Genes, p53 | 1 | 2001 | 109 | 0.050 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2001 | 114 | 0.050 |
Why?
|
Biomarkers, Tumor | 2 | 2010 | 1464 | 0.050 |
Why?
|
Cytogenetic Analysis | 1 | 2000 | 71 | 0.050 |
Why?
|
Platelet Count | 1 | 2000 | 92 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2004 | 683 | 0.050 |
Why?
|
Antigens, CD | 2 | 2003 | 458 | 0.050 |
Why?
|
Cell Movement | 1 | 2004 | 758 | 0.050 |
Why?
|
Iron Chelating Agents | 1 | 2000 | 4 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2006 | 2380 | 0.050 |
Why?
|
Health Planning Guidelines | 1 | 2019 | 24 | 0.050 |
Why?
|
Lymphoma, Follicular | 2 | 1998 | 70 | 0.050 |
Why?
|
Communicable Disease Control | 1 | 2020 | 51 | 0.050 |
Why?
|
Autoimmune Diseases | 1 | 2002 | 241 | 0.040 |
Why?
|
Patient Selection | 2 | 2019 | 685 | 0.040 |
Why?
|
Health Care Rationing | 1 | 2020 | 83 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
Genetic Markers | 1 | 2000 | 476 | 0.040 |
Why?
|
Standard of Care | 1 | 2019 | 79 | 0.040 |
Why?
|
Iron | 1 | 2000 | 164 | 0.040 |
Why?
|
Aspergillus | 1 | 1998 | 9 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2019 | 87 | 0.040 |
Why?
|
Age Factors | 2 | 2015 | 1851 | 0.040 |
Why?
|
Dioxygenases | 1 | 2019 | 74 | 0.040 |
Why?
|
Gastroparesis | 1 | 1998 | 14 | 0.040 |
Why?
|
Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
Aspergillosis | 1 | 1998 | 41 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2011 | 122 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 270 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2019 | 265 | 0.040 |
Why?
|
Premedication | 1 | 2017 | 54 | 0.040 |
Why?
|
Tacrolimus | 1 | 2019 | 373 | 0.040 |
Why?
|
Palliative Care | 1 | 2019 | 257 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 257 | 0.040 |
Why?
|
Nausea | 1 | 1998 | 175 | 0.040 |
Why?
|
Hematopoietic Cell Growth Factors | 1 | 1997 | 11 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 376 | 0.040 |
Why?
|
Ukraine | 1 | 1997 | 14 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 2 | 2015 | 272 | 0.040 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 1996 | 7 | 0.040 |
Why?
|
Vomiting | 1 | 1998 | 193 | 0.040 |
Why?
|
Blast Crisis | 1 | 1996 | 33 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2019 | 751 | 0.040 |
Why?
|
Parkinson Disease, Secondary | 1 | 1996 | 4 | 0.040 |
Why?
|
Phosphorylation | 1 | 2019 | 1106 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2019 | 639 | 0.030 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.030 |
Why?
|
Pentostatin | 1 | 2015 | 30 | 0.030 |
Why?
|
Immunotherapy | 1 | 2021 | 629 | 0.030 |
Why?
|
Rabbits | 1 | 1996 | 636 | 0.030 |
Why?
|
Complementarity Determining Regions | 1 | 2015 | 24 | 0.030 |
Why?
|
Methotrexate | 1 | 1995 | 249 | 0.030 |
Why?
|
Mice | 3 | 2004 | 11352 | 0.030 |
Why?
|
Mortality | 1 | 2016 | 149 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 2011 | 927 | 0.030 |
Why?
|
Transplant Recipients | 1 | 2015 | 122 | 0.030 |
Why?
|
Prevalence | 1 | 2018 | 1239 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 1996 | 3030 | 0.030 |
Why?
|
Patient Outcome Assessment | 1 | 2013 | 84 | 0.030 |
Why?
|
Mental Health | 1 | 2013 | 162 | 0.030 |
Why?
|
Cell Division | 3 | 2001 | 696 | 0.030 |
Why?
|
Sarcoma, Ewing | 1 | 2012 | 42 | 0.030 |
Why?
|
Tumor Cells, Cultured | 3 | 2001 | 1041 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2013 | 557 | 0.030 |
Why?
|
Data Collection | 1 | 2013 | 372 | 0.030 |
Why?
|
Social Adjustment | 1 | 2011 | 46 | 0.020 |
Why?
|
Hematology | 1 | 2011 | 29 | 0.020 |
Why?
|
Mitogens | 2 | 2003 | 64 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2010 | 1197 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 426 | 0.020 |
Why?
|
Japan | 1 | 2011 | 307 | 0.020 |
Why?
|
Chromosome Banding | 1 | 2010 | 74 | 0.020 |
Why?
|
Bone Marrow | 2 | 2007 | 435 | 0.020 |
Why?
|
DNA, Viral | 1 | 2011 | 265 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2013 | 1019 | 0.020 |
Why?
|
Dasatinib | 1 | 2010 | 37 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2010 | 69 | 0.020 |
Why?
|
Sclerosis | 1 | 2010 | 28 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2007 | 999 | 0.020 |
Why?
|
RNA, Viral | 1 | 2011 | 327 | 0.020 |
Why?
|
Treatment Failure | 1 | 2010 | 285 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2012 | 322 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2009 | 84 | 0.020 |
Why?
|
Radiation Tolerance | 1 | 2010 | 168 | 0.020 |
Why?
|
Data Mining | 1 | 2009 | 42 | 0.020 |
Why?
|
Phenotype | 1 | 2015 | 2378 | 0.020 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2009 | 81 | 0.020 |
Why?
|
Antigen Presentation | 1 | 2010 | 209 | 0.020 |
Why?
|
Leukapheresis | 1 | 2008 | 19 | 0.020 |
Why?
|
Blood Cell Count | 1 | 2008 | 79 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2010 | 143 | 0.020 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2008 | 2 | 0.020 |
Why?
|
Natural Cytotoxicity Triggering Receptor 3 | 1 | 2008 | 2 | 0.020 |
Why?
|
CD56 Antigen | 1 | 2008 | 18 | 0.020 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2008 | 20 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2008 | 29 | 0.020 |
Why?
|
Contraindications | 1 | 2007 | 72 | 0.020 |
Why?
|
Administration, Topical | 1 | 2007 | 95 | 0.020 |
Why?
|
Primary Myelofibrosis | 1 | 2008 | 56 | 0.020 |
Why?
|
Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 5 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 879 | 0.020 |
Why?
|
Lactoferrin | 1 | 2007 | 11 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 27 | 0.020 |
Why?
|
beta 2-Microglobulin | 1 | 2007 | 24 | 0.020 |
Why?
|
Truth Disclosure | 1 | 2007 | 87 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 74 | 0.020 |
Why?
|
Immunoglobulin A | 1 | 2007 | 80 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2007 | 103 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 592 | 0.020 |
Why?
|
CD4-CD8 Ratio | 1 | 2006 | 18 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 469 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2000 | 429 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2010 | 479 | 0.020 |
Why?
|
Biomedical Research | 1 | 2010 | 376 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2009 | 2062 | 0.020 |
Why?
|
Bone Marrow Cells | 2 | 1998 | 253 | 0.020 |
Why?
|
Antimetabolites | 1 | 2003 | 24 | 0.010 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2003 | 27 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2004 | 188 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2011 | 2501 | 0.010 |
Why?
|
Allopurinol | 1 | 2003 | 80 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2008 | 2818 | 0.010 |
Why?
|
Cell Count | 1 | 2003 | 195 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 48 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2003 | 148 | 0.010 |
Why?
|
Skin | 1 | 2005 | 554 | 0.010 |
Why?
|
Safety | 1 | 2002 | 152 | 0.010 |
Why?
|
Drug Synergism | 1 | 2001 | 303 | 0.010 |
Why?
|
Biological Transport | 1 | 2001 | 396 | 0.010 |
Why?
|
DNA Primers | 1 | 2001 | 543 | 0.010 |
Why?
|
Spectrophotometry, Atomic | 1 | 2000 | 12 | 0.010 |
Why?
|
Erythrocyte Count | 1 | 2000 | 23 | 0.010 |
Why?
|
Cadmium | 1 | 2000 | 28 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 2000 | 121 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2000 | 172 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2003 | 728 | 0.010 |
Why?
|
Neutropenia | 1 | 2000 | 215 | 0.010 |
Why?
|
Copper | 1 | 2000 | 71 | 0.010 |
Why?
|
Chelating Agents | 1 | 2000 | 69 | 0.010 |
Why?
|
Zinc | 1 | 2000 | 91 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2006 | 1458 | 0.010 |
Why?
|
Erythromycin | 1 | 1998 | 9 | 0.010 |
Why?
|
Gastric Emptying | 1 | 1998 | 23 | 0.010 |
Why?
|
Toxicity Tests | 1 | 1998 | 13 | 0.010 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 1998 | 7 | 0.010 |
Why?
|
K562 Cells | 1 | 1998 | 43 | 0.010 |
Why?
|
Kinetics | 1 | 2001 | 1513 | 0.010 |
Why?
|
Nuclear Family | 1 | 1998 | 92 | 0.010 |
Why?
|
Microbial Sensitivity Tests | 1 | 1998 | 143 | 0.010 |
Why?
|
Coculture Techniques | 1 | 1998 | 164 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2000 | 297 | 0.010 |
Why?
|
Mice, SCID | 1 | 1998 | 252 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 391 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 1998 | 163 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 1998 | 196 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2000 | 454 | 0.010 |
Why?
|
Gastrointestinal Agents | 1 | 1998 | 161 | 0.010 |
Why?
|
Haloperidol | 1 | 1996 | 30 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2000 | 865 | 0.010 |
Why?
|
Levodopa | 1 | 1996 | 36 | 0.010 |
Why?
|
Carmustine | 1 | 1996 | 70 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 1961 | 0.010 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 1996 | 138 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1996 | 276 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2000 | 1981 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 1994 | 468 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1993 | 40 | 0.010 |
Why?
|
Case-Control Studies | 1 | 1994 | 1805 | 0.010 |
Why?
|
Base Sequence | 1 | 1993 | 2330 | 0.010 |
Why?
|